PLC is pleased to announce that a New Drug Application for seizure rescue treatment VALTOCO® (Diazepam nasal spray) has been filed on behalf of Neurelis with the US FDA

Sep

by Tracy Paul

24 September 2018 – PLC is pleased to announce that a New Drug Application for seizure rescue treatment VALTOCO^® (Diazepam nasal spray) has been filed on behalf of Neurelis with the US FDA. PLC has supported Neurelis with VALTOCO from program inception and supported their IND filings, clinical development programs and provided clinical oversight for their trials.

NEURELIS FILES NEW DRUG APPLICATION WITH THE FDA FOR VALTOCO™ (DIAZEPAM NASAL SPRAY), AN INVESTIGATIONAL TREATMENT FOR PEDIATRIC, ADOLESCENT AND ADULT EPILEPSY PATIENTS

https://neurelis.com/neurelis-news/neurelis-files-new-drug-application-fda-valtocotm-nasal-spray-investigational-treatment-pediatric

Written by Tracy Paul

Translate »

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Experience, Reliable, Effective

Congratulations to Indivior on the US FDA approval of their opioid overdose rescue medication for natural and synthetic opioids, OPVEE® (nalmefene) Nasal Spray

PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®

Written by Tracy Paul

Related Posts

PLC congratulates ARS Pharmaceuticals on their recent announcement of FDA acceptance of the NDA for neffy® for the treatment of allergic reactions including anaphylaxis

PLC would like to recognize Adapt Pharma and Lightlake Therapeutics, partners developing a naloxone-based nasal spray for opioid overdose reversal, on their recent NDA submission to the US FDA